Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Aditi Kadakia, Brenna L. Brady, Carole Dembek, G. Rhys Williams & Justine M. Kent. (2022) The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population. Journal of Medical Economics 25:1, pages 87-98.
Read now
Read now
Brian Keogh, Esther Murphy, Louise Doyle, Greg Sheaf, Mike Watts & Agnes Higgins. (2022) Mental health service users experiences of medication discontinuation: a systematic review of qualitative studies. Journal of Mental Health 31:2, pages 227-238.
Read now
Read now
Myrlene S Aigbogun, Sizhu Liu, Siddhesh A Kamat, Christophe Sapin, Amy M Duhig & Leslie Citrome. (2018) Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. ClinicoEconomics and Outcomes Research 10, pages 443-456.
Read now
Read now
Ruggero Andrisano-Ruggieri, Pietro Crescenzo, Rosa Ambrosio, Gaetano Pinto & Francesco Grieco. (2016) Building therapeutic relationship in schizophrenic and alcohol-related disorder cases. Psychodynamic Practice 22:3, pages 236-252.
Read now
Read now
Wenyu Ye, William Montgomery, Zbigniew Kadziola, Li Liu, Haibo Xue, Michael D Stensland & Tamas Treuer. (2014) Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People’s Republic of China. Neuropsychiatric Disease and Treatment 10, pages 869-878.
Read now
Read now
William Montgomery, Li Liu, Michael D Stensland, Hai Bo Xue, Tamas Treuer & Haya Ascher-Svanum. (2013) The personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapy. ClinicoEconomics and Outcomes Research 5, pages 407-418.
Read now
Read now
Vidya Perera, Annette S Gross, Thomas M Polasek, Yan Qin, Gauri Rao, Alan Forrest, Junzhe Xu & Andrew J McLachlan. (2013) Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. Expert Opinion on Drug Metabolism & Toxicology 9:9, pages 1115-1137.
Read now
Read now
Louis S Matza, Glenn A Phillips, Dennis A Revicki, Haya Ascher-Svanum, Karen G Malley, Andrew C Palsgrove, Douglas E Faries, Virginia Stauffer, Bruce J Kinon, A George Awad, Richard SE Keefe & Dieter Naber. (2012) Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation. Patient Preference and Adherence 6, pages 521-532.
Read now
Read now
Jian Chen, Haya Ascher-Svanum, Allen W Nyhuis, Michael G Case, Glenn A Phillips, Kory J Schuh & Vicki Poole Hoffmann. (2011) Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians. Patient Preference and Adherence 5, pages 547-554.
Read now
Read now
Articles from other publishers (28)
Björn Schlier, Laura Buck, Rebecca Müller, Tania M. Lincoln, Antonia Bott & Matthias Pillny. (2023) Time-dependent effect of antipsychotic discontinuation and dose reduction on social functioning and subjective quality of life–a multilevel meta-analysis. eClinicalMedicine 65, pages 102291.
Crossref
Crossref
Ferenc Fekete, Ádám Menus, Katalin Tóth, Ádám Ferenc Kiss, Annamária Minus, Dávid Sirok, Aleš Belič, Ádám Póti, Gábor Csukly & Katalin Monostory. (2023) CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients. Scientific Reports 13:1.
Crossref
Crossref
Anne Emilie Stürup, Carsten Hjorthøj, Heidi Dorthe Jensen, Marianne Melau, Josefine Winther Davy, Merete Nordentoft & Nikolai Albert. (2023) Self‐reported reasons for discontinuation or continuation of antipsychotic medication in individuals with first‐episode schizophrenia. Early Intervention in Psychiatry.
Crossref
Crossref
John M. Kane & Jose M. Rubio. (2023) The place of long-acting injectable antipsychotics in the treatment of schizophrenia. Therapeutic Advances in Psychopharmacology 13, pages 204512532311572.
Crossref
Crossref
Rui Cai, Flore Decuypere, Pierre Chevalier, Martin Desseilles, Martin Lambert, Eric Fakra, Antonie Wimmer, Pascal Guillon, Stefan Pype, Annabelle Godet & Valeria Borgmeier. (2022) Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium. BMC Psychiatry 22:1.
Crossref
Crossref
John M. Kane. (2022) A New Treatment Paradigm. Journal of Clinical Psychopharmacology 42:5, pages S1-S13.
Crossref
Crossref
Miriam Boland, Agnes Higgins, Claire Beecher, Pat Bracken, Wendy Burn, Anne Cody, Adele Framer, Toto Anne Gronlund, Mark Horowitz, Christy Huff, Sandra Jayacodi, Dolores Keating, David Kessler, Asa Konradsson Geuken, Nicole Lamberson, Luke Montagu, Brian Osborne, Ruth Smith & Cathal Cadogan. (2022) Priorities for future research on reducing and stopping psychiatric medicines using a James Lind Alliance priority setting partnership: The PROTECT study protocol. HRB Open Research 5, pages 72.
Crossref
Crossref
Johanna Seifert, Stefan Bleich & Roland Seifert. 2022. Arzneiverordnungs-Report 2022. Arzneiverordnungs-Report 2022
451
495
.
Aline Gazzola Fragnani Valença & Bradley Joseph Smith. 2022. Neuroproteomics as a Tool for Understanding Schizophrenia. Neuroproteomics as a Tool for Understanding Schizophrenia
53
63
.
Henry A. Nasrallah, Peter J. Weiden, David P. Walling, Yangchun Du, Baiyun Yao, Sergey Yagoda & Amy Claxton. (2021) Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study. BMC Psychiatry 21:1.
Crossref
Crossref
Mike WattsDrDr, Esther Murphy, Brian KeoghDrDr, Carmel Downes, Louise Doyle & Agnes Higgins. (2021) Deciding to discontinue prescribed psychotropic medication: A qualitative study of service users’ experiences. International Journal of Mental Health Nursing 30:S1, pages 1395-1406.
Crossref
Crossref
Gerhard Gründer, Philipp Bauknecht, Stefan Klingberg, Karolina Leopold, Michael Paulzen, Stefanie Schell, Katarina Stengler & Stefan Leucht. (2020) Treatment Goals for Patients with Schizophrenia — A Narrative Review of Physician and Patient Perspectives. Pharmacopsychiatry 54:02, pages 53-59.
Crossref
Crossref
Stephanie Clements, Francesca Coniglio & Lynette Mackenzie. (2019) “I’m Not Telling an Illness Story. I’m Telling a Story of Opportunity”: Making Sense of Voice Hearing Experiences. Community Mental Health Journal 56:2, pages 196-205.
Crossref
Crossref
Zhang Cheng, Yanbo Yuan, Xue Han, Lei Yang, Xin Zeng, Fude Yang, Zheng Lu, Chuanyue Wang, Hong Deng, Jingping Zhao, Yu-Tao Xiang, Christoph U. Correll & Xin Yu. (2019) Rates and predictors of one-year antipsychotic treatment discontinuation in first-episode schizophrenia: Results from an open-label, randomized, “real world” clinical trial. Psychiatry Research 273, pages 631-640.
Crossref
Crossref
John W. Newcomer, Daisy Ng-Mak, Krithika Rajagopalan & Antony Loebel. (2018) Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis. BMC Health Services Research 18:1.
Crossref
Crossref
Marta Miarons, Christopher Cabib, Francisco Javier Barón & Laia Rofes. (2017) Evidence and decision algorithm for the withdrawal of antipsychotic treatment in the elderly with dementia and neuropsychiatric symptoms. European Journal of Clinical Pharmacology 73:11, pages 1389-1398.
Crossref
Crossref
Miriam Wade, Sara Tai, Yvonne Awenat & Gillian Haddock. (2017) A systematic review of service-user reasons for adherence and nonadherence to neuroleptic medication in psychosis. Clinical Psychology Review 51, pages 75-95.
Crossref
Crossref
Suresh Durgam, William M. Greenberg, Dayong Li, Kaifeng Lu, Istvan Laszlovszky, Gyorgy Nemeth, Raffaele Migliore & Stephen Volk. (2016) Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology 234:2, pages 199-209.
Crossref
Crossref
Steffen Moritz, Alexandra Hünsche & Tania M. Lincoln. (2014) Nonadherence to antipsychotics: The role of positive attitudes towards positive symptoms. European Neuropsychopharmacology 24:11, pages 1745-1752.
Crossref
Crossref
Vidya Perera, Robert R. Bies, Gary Mo, Michael J. Dolton, Vaughan J. Carr, Andrew J. McLachlan, Richard O. Day, Thomas M. Polasek & Alan Forrest. (2014) Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. British Journal of Clinical Pharmacology 78:4, pages 800-814.
Crossref
Crossref
Francisco J. Acosta, Yolanda Ramallo-Fariña, Esperanza Bosch, Teresa Mayans, Carlos J. Rodríguez & Ana Caravaca. (2013) Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS®). Schizophrenia Research 146:1-3, pages 196-200.
Crossref
Crossref
Lars Eriksson, Teresa Hallerbäck, Leif Jørgensen & Andreas Carlborg. (2012) Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schizophrenia: a retrospective study. Therapeutic Advances in Psychopharmacology 2:6, pages 217-226.
Crossref
Crossref
Louis S. Matza, Glenn A. Phillips, Dennis A. Revicki, Haya Ascher-Svanum, Karen G. Malley, Andrew C. Palsgrove, Douglas E. Faries, Virginia Stauffer, Bruce J. Kinon, A. George Awad, Richard S.E. Keefe & Dieter Naber. (2012) Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. Psychiatry Research 200:2-3, pages 835-842.
Crossref
Crossref
J. J. Stephenson, O. Tuncelli, T. Gu, D. Eisenberg, J. Panish, C. Crivera & R. Dirani. (2012) Adherence to oral second‐generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims. International Journal of Clinical Practice 66:6, pages 565-573.
Crossref
Crossref
Linda Simoni-Wastila, Yu-Jung Wei, Jingjing Qian, Ilene H. Zuckerman, Bruce Stuart, Thomas Shaffer, Anand A. Dalal & Lynda Bryant-Comstock. (2012) Association of Chronic Obstructive Pulmonary Disease Maintenance Medication Adherence With All-Cause Hospitalization and Spending in a Medicare Population. The American Journal of Geriatric Pharmacotherapy 10:3, pages 201-210.
Crossref
Crossref
Jason M. Uslaner, Sean M. Smith, Sarah L. Huszar, Rashida Pachmerhiwala, Richard M. Hinchliffe, Joshua D. Vardigan, Shannon J. Nguyen, Nathan O. Surles, Lihang Yao, James C. Barrow, Victor N. Uebele, John J. Renger, Janet Clark & Pete H. Hutson. (2012) T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats. Neuropharmacology 62:3, pages 1413-1421.
Crossref
Crossref
Hong Liu-Seifert, Olawale O. Osuntokun & Peter D. Feldman. (2012) Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia. Comprehensive Psychiatry 53:1, pages 107-115.
Crossref
Crossref
Michael Musker, Martin David Lewis, Geoffrey Schrader, Vivian Isaac, Jörg Strobel & Niranjan Bidargaddi. (2021) Defining Medication Discontinuation From Prescription Claims Records to Initiate Clinical Intervention in Schizophrenia & Bipolar Disorder: A Systematic Review. SSRN Electronic Journal.
Crossref
Crossref